Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | PDE1A | P54750 | 4/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070317 | 0.75 | CRHR1 (0.36) | CRHR1KDM4EMAPK1POLBSMN1; SMN2 | |
| SCHEMBL2070072 | 0.75 | ELANE (0.33) | CRHR1MAPK1MAPTMAPK10 | |
| SCHEMBL2070502 | 0.74 | CRHR1 (0.36) | CRHR1MAPK1MAPTMAPK10 | |
| SCHEMBL2070525 | 0.72 | PDE1A (0.39) | PDE1APDE1BPDE1CKDM4EMAPK1 | |
| SCHEMBL2072373 | 0.71 | MAPK10 (0.38) | CRHR1ALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL2069533 | 0.71 | MAPK10 (0.36) | CRHR1ALDH1A1MAPK1POLBNPC1 | |
| SCHEMBL2072012 | 0.68 | SHMT2 (0.48) | CRHR1ALDH1A1KDM4EMAPK1SMN1; SMN2 | |
| SCHEMBL2071304 | 0.67 | DRD2 (0.37) | PDE1APDE1BPDE1CPDE2A | |
| SCHEMBL2069962 | 0.67 | C5AR1 (0.36) | MAPK1SMN1; SMN2LMNATP53MAPK10 | |
| SCHEMBL2069530 | 0.67 | CRHR1 (0.37) | CRHR1KDM4EMAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522670-A1 | Heterocyclic CRF receptor antagonists | Takeda Pharmaceutical Company Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-7897607-B2 | Cyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
| US-20070179165-A1 | Cyclic compounds | GYORKOS ALBERT C | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179165-A1 | Cyclic compounds | CRHR1, CRHR2, MC2R | CRHR1 1/4885ALDH1A1 786/4885PDE1A 908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.